Asthma: Beyond corticosteroid treatment

Archives of Medical Science

Volumn 9, Issue 3, 2013, Pages 521-526

  Marandi, Yasser ^a   Farahi, Neda ^b   Hashjin, Goudarz Sadeghi ^c  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Asthma; Corticosteroids; Inflammation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYTOKINE ANTIBODY; FLUTICASONE FUROATE; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 9 ANTIBODY; MEPOLIZUMAB; MUSCARINIC RECEPTOR BLOCKING AGENT; OMALIZUMAB; PEPTIDOLEUKOTRIENE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN KINASE SYK INHIBITOR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ARTICLE; ASTHMA; BACTERIAL INFECTION; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DRUG BINDING; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EOSINOPHIL; HUMAN; IMMUNOTHERAPY; MAST CELL; UNSPECIFIED SIDE EFFECT;

EID: 84879828223     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.33179     Document Type: Article

References (50)

1. Hamid QA, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009; 71: 489-507.
2. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157: S1-53.
3. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817-22.
4. Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99: 879-87. (Pubitemid 27123624)
5. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-93.
6. Barnes PJ. How corticosteroids control inflammation. Quintiles Prize Lecture. Br J Pharmacol 2005; 48: 245-54. (Pubitemid 43804814)
7. Hamid QA, Wenzel SE, Hauk PJ, et al. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999; 159: 160-4.
8. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003; 178: 347-55. (Pubitemid 37220162)
9. Caramori G, Papi A. Oxidants and asthma. Thorax 2004; 59: 170-3. (Pubitemid 38228419)
10. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-57. (Pubitemid 34327193)
11. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004; 113: 1100-8. (Pubitemid 38857992)
12. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ. Abnormal glucocorticoid receptor/AP-1 interaction in steroid resistant asthma. J Exp Med 1995; 182: 1951-8.
13. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced anti-body-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125: 1344-53.
14. Antoniu SA. MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther 2010; 12: 233-9.
15. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med 2010; 10: 3.
16. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183: 1007-14.
17. Mullane K. Asthma translational medicine: report card. Biochem Pharmacol 2011; 82: 567-85.
18. Placebo-controlled phase II study shows CYT003-QbG10 is safe and efficacious for the treatment of allergic asthma. Press release May 21, 2010. http://www.cytos.com/userfiles/file/Cytos-Press-E-100521.pdf.
19. Rigel says Pfizer returns asthma therapy rights. Press release May 6, 2011. http://www.rigel.com/.
20. Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009; 64: 1194-201.
21. Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010; 11: 26.
22. O'Byrne PM. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007; 176: 1059-60. (Pubitemid 350223749)
23. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-21. (Pubitemid 35447900)
24. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-8.
25. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
26. Wenzel SE, Barnes PJ, Bleecker ER, et al.; T03 Asthma Investigators. A randomized, double-blind placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-58.
27. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4R-alpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788-96.
28. Singh J, Adams S, Carter MB, et al. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr Top Med Chem 2004; 4: 1497-507. (Pubitemid 39317605)
29. Okigami H, Takeshita K, Tajimi M, et al. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Eur J Pharmacol 2007; 559: 202-9. (Pubitemid 46295402)
30. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R, Wolff G. Bimosiamose, an inhaled small-molecule panselectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2006; 19: 233-41.
31. Brode S, Farahi N, Cowburn AS, Juss JK, Condliffe AM, Chilvers ER. Interleukin-5 inhibits glucocorticoid-mediated apoptosis in human eosinophils. Thorax 2010; 65: 1116-7.
32. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: L660-7. (Pubitemid 47358828)
33. Van den Berge M, Luijk B, Bareille P, Dallow N, Postma DS, Lammers JW. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010; 65: 1531-5.
34. GlaxoSmithKline commences Relovair Phase III asthma programme. Press release 19 March 2010. http://www.gsk.com/media/.
35. Schaecke H, Schottelius A, Döcke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227-32. (Pubitemid 38084232)
36. De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem. Mol Biol 2010; 120: 96-104.
37. Camps M, Ruckle T, Ji H, et al. Blockade of PI3K-gamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-43. (Pubitemid 41294438)
38. Sadhu C, Masinovsky B, Dick K, et al. Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma. J Allergy Clin Immunol 2011; 127: 1632-4.
39. Hasan AM, Mourtada-Maarabouni M, Hameed MS, Williams GT, Dent G. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol 2010; 10: 1017-21.
40. Ameriks MK, Venable JD. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma. Curr Top Med Chem 2009; 9: 738-53.
41. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 897-904.
42. Park SJ, Lee KS, Kim SR, et al. Phosphoinositide 3-kinase delta inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur Respir J 2010; 36: 1448-59.
43. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 1: 16-21.
44. Hallett JM, Leitch AE, Riley NA, Duffin R, Haslett C, Rossi AG. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol Sci 2008; 29: 250-7.
45. Duffin R, Leitch AE, Sheldrake TA, et al. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by downregulation of Mcl-1. FEBS Lett 2009; 583: 2540-6.
46. Farahi N, Uller L, Juss JK, et al. Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance. Clin Exp Allergy 2011; 41: 673-87.
47. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nature Reviews Drug Discovery 2009; 8: 547-66.
48. Gilchrist M, Henderson WR Jr, Clark AE, et al. Activating transcription factor 3 is a negative regulator of allergic pulmonary inflammation. J Exp Med 2008; 205: 2349-57.
49. Jiang X. The emerging role of microRNAs in asthma. Mol Cell Biochem 2011; 353: 35-40.
50. Collison A, Mattes J, Plank M, Foster PS. Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. J Allergy Clin Immunol 2011; 128: 160-7.